Search
forLearn
5 / 801 resultslearn platycladus orientalis
learn Selenium sulfide
learn scutellaria baicalensis
learn choline bitartrate
Research
5 / 1000+ results
research Epidermal keratinocytes initiate wound healing and pro-inflammatory immune responses following percutaneous schistosome infection
Epidermal keratinocytes start wound healing and inflammation after schistosome infection.
research Comparative biology of tissue repair, regeneration and aging
The symposium concluded that understanding how different species repair tissue and how this changes with age can help advance regenerative medicine.
research Diagnosis of sports‐related dermatoses
Different sports can cause specific skin conditions that need proper diagnosis and treatment.
research Antihelminthic Drugs
Antihelminthic drugs treat worm infections but face challenges like low treatment coverage and potential drug resistance, with various side effects reported for different drugs.
research In vitro Evaluation of Nerium oleander Leaf Extract against Sarcoptes scabiei var. cuniculi Mite Isolated from Naturally Infested Rabbits
Nerium oleander leaf extract effectively kills scabies mites in rabbits.
Community Join
5 / 1000+ resultscommunity Clascoterone full results in July
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community European release of clascoterone
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
community Clascoterone study going on right now
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
community Clascoterone 12 months phase 3 result out
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.